Drug intelligence / Profile preview

MesoStem

Development stage: Preclinical
Lead developer: Escape Therapeutics
Modality: Stem Cell Therapies → Cell Therapies

Overview

MesoStem is an allogeneic, "universal" adult-derived mesenchymal stromal cell (MSC) therapy being developed by Escape Therapeutics. It is designed to treat Type 1 diabetes by leveraging the immunomodulatory and tissue-repair properties of MSCs. The "universal" aspect suggests these cells are engineered or selected to be immune-tolerant, allowing for off-the-shelf use without the need for patient-specific HLA matching. In the context of Type 1 diabetes, the therapy likely aims to preserve remaining beta-cell function or support the regeneration of pancreatic tissue through the secretion of paracrine factors and direct cellular interactions.

Brand names: MesoStem
Other names: Universal adult-derived MSCs

Beyond the preview

Go deeper on MesoStem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MesoStem.

Explore the full profile